The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Self-Protecting Biomimetic Nanozyme for Selective and Synergistic Clearance of Peripheral Amyloid-β in an Alzheimer’s Disease Model
Abstract
Clearance of peripheral amyloid-β (Aβ) has been demonstrated to be promising for overcoming the blood–brain barrier (BBB) hurdle to eliminate brain-derived Aβ associated with Alzheimer’s disease (AD). Even so, current developed therapeutic assays for clearance of peripheral Aβ are still facing challenges on how to avoid interference of certain biological molecules and prevent triggering the activation of immune responses and blood clotting. Here, a biomimetic nanozyme (Cu x O@EM-K) with augmented protein adsorption resistance, minimized immunogenicity, and enhanced biocompatibility is designed and synthesized. The Cu x O@EM-K is made of Cu x O nanozyme wrapped with modified 3xTg-AD mouse erythrocyte membrane with Aβ-targeting pentapeptide KLVFF. KLVFF serves as Aβ-specific ligand that works together with erythrocyte membrane to selectively capture Aβ in the blood. Meanwhile, the erythrocyte membrane coating prevents protein coronas formation and thus retains Aβ-targeting ability of Cu x O@EM-K in biological fluids. More importantly, the Cu x O core with multiple antioxidant enzyme-like activities stabilizes the outer erythrocyte membrane and simultaneously mitigates Aβ-induced membrane oxidative damage, which enables the extended systemic circulation indispensable for adsorbing Aβ. In vivo studies demonstrate that Cu x O@EM-K not only reduces Aβ burden in the blood and brain but also ameliorates memory deficits in the widely used 3xTg-AD mouse model. Moreover, Cu x O@EM-K shows no apparent toxicity in 3xTg-AD mice. Overall, this work provides an example for developing biocompatible and synergistic clearance of peripheral Aβ associated with AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
Astrocyte-endothelial interactions at the blood-brain barrier
Abbott, N. J., Rönnbäck, L., & Hansson, E. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1824 · Cited by 5,595
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
Knop, K., Hoogenboom, R., Fischer, D., & Schubert, U. S. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200902672 · Cited by 3,533
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
Cell Membrane Coating Nanotechnology
Fang, R. H., Kroll, A. V., Gao, W., & Zhang, L. (2018) · Advanced Materials · doi:10.1002/adma.201706759 · Cited by 1,885
DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298
The blood-brain barrier in Alzheimer’s disease
Zenaro, E., Piacentino, G., & Constantin, G. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.07.007 · Cited by 767
Increased in Vivo Amyloid-β42 Production, Exchange, and Loss in Presenilin Mutation Carriers
Potter, R., Patterson, B. W., Elbert, D. L., Ovod, V., Kasten, T., Sigurdson, W., Mawuenyega, K., Blazey, T., Goate, A., Chott, R., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005615 · Cited by 236
Systemic Catabolism of Alzheimer's Aβ40 and Aβ42
Ghiso, J., Shayo, M., Calero, M., Ng, D., Tomidokoro, Y., Gandy, S., Rostagno, A., & Frangione, B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407668200 · Cited by 209
Peripheral clearance of amyloid β peptide by complement C3-dependent adherence to erythrocytes
Rogers, J., Li, R., Mastroeni, D., Grover, A., Leonard, B., Ahern, G., Cao, P., Kolody, H., Vedders, L., Kolb, W. P., et al. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.09.043 · Cited by 175
Deaths from Alzheimer’s Disease — United States, 1999–2014
Taylor, C. A., Greenlund, S. F., McGuire, L. C., Lu, H., & Croft, J. B. (2017) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6620a1 · Cited by 144
Blood cell-produced amyloid-β induces cerebral Alzheimer-type pathologies and behavioral deficits
Sun, H.-L., Chen, S.-H., Yu, Z.-Y., Cheng, Y., Tian, D.-Y., Fan, D.-Y., He, C.-Y., Wang, J., Sun, P.-Y., Chen, Y., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0842-1 · Cited by 56
Cited by
A Review on Metal- and Metal Oxide-Based Nanozymes: Properties, Mechanisms, and Applications
Liu, Q., Zhang, A., Wang, R., Zhang, Q., & Cui, D. (2021) · Nano-Micro Letters · doi:10.1007/s40820-021-00674-8 · Cited by 745
Huang, Y., Guo, X., Wu, Y., Chen, X., Feng, L., Xie, N., & Shen, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01745-z · Cited by 490
Designing nanozymes for in vivo applications
Zhang, R., Jiang, B., Fan, K., Gao, L., & Yan, X. (2024) · Nature Reviews Bioengineering · doi:10.1038/s44222-024-00205-1 · Cited by 360
Zhang, Y., Wei, G., Liu, W., Li, T., Wang, Y., Zhou, M., Liu, Y., Wang, X., & Wei, H. (2024) · Nature Reviews Methods Primers · doi:10.1038/s43586-024-00315-5 · Cited by 350
Biosystem‐Inspired Engineering of Nanozymes for Biomedical Applications
Zhang, L., Wang, H., & Qu, X. (2024) · Advanced Materials · doi:10.1002/adma.202211147 · Cited by 297
Self-citation
Metadata
- Authors
- Ma, M., Liu, Z., Gao, N., Pi, Z., Du, X., Ren, J., & Qu, X.
- Venue
- Journal of the American Chemical Society
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-12-16
- Volume
- 142
- Issue
- 52
- Pages
- 21702-21711
- ISSN
- 0002-7863 (ISSN-L)
- 1520-5126
- OpenAlex
- W3113078272
- Cited by
- 187
- References
- 12
- FWCI
- 8.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.